Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

Among 200 dialysis patients, 37% were non-compliant with their phosphate binders compared with 12% to 18% of patients who ...

A study from researchers at the Tehran University of Medical Sciences has found that psilocin significantly reduced ...

Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 inOpen-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced ...

Hoth Therapeutics, Inc.(NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs, today announced positive interim data from the ...

Series C round led by Deep Track Capital with participation from additional new and existing investorsFinancing will fund early-to-mid-stage ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of its ...

Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...

Ruxolitinib 1.5% cream significantly reduces pruritus and lesion severity among adults with prurigo nodularis for up to 12 weeks of treatment.

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

Initial pediatric subject shows sustained benefit with QRX003; second patient approved for full-body treatment in ongoing ...